Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths
Related Experiment Video
Updated: Jul 26, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Sepideh Karkon-Shayan1, Hasan Aliashrafzadeh2, Hassan Dianat-Moghadam3
1Student Research Committee, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
Abstract:
Glioblastoma multiforme (GBM) is one of the most aggressive brain and spinal cord tumors. Despite the significant development in application of antitumor drugs, no significant increases have been observed in the survival rates of patients with GBM, as GBM cells acquire resistance to conventional anticancer therapeutic agents. Multiple studies have revealed that PI3K/Akt, MAPK, Nanog, STAT 3, and Wnt signaling pathways are involved in GBM progression and invasion. Besides, biological processes such as anti-apoptosis, autophagy, angiogenesis, and stemness promote GBM malignancy. Resveratrol (RESV) is a non-flavonoid polyphenol with high antitumor activity, the potential of which, regulating signaling pathways involved in cancer malignancy, have been demonstrated by many studies. Herein, we present the potential of RESV in both single and combination therapy- targeting various signaling pathways- which induce apoptotic cell death, re-sensitize cancer cells to radiotherapy, and induce chemo-sensitizing effects to eventually inhibit GBM progression.
Insights
Resveratrol (RESV) shows promise in treating glioblastoma multiforme (GBM) by targeting key cancer pathways. This natural compound may enhance current therapies, improving outcomes for aggressive brain tumor patients.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with poor patient survival rates.
- GBM cells develop resistance to conventional therapies, necessitating novel treatment strategies.
- Key signaling pathways (PI3K/Akt, MAPK, Nanog, STAT3, Wnt) and biological processes (anti-apoptosis, autophagy, angiogenesis, stemness) drive GBM malignancy.
Purpose of the Study:
- To explore the potential of Resveratrol (RESV) as an anti-cancer agent against glioblastoma.
- To investigate RESV's efficacy in both single and combination therapeutic approaches.
- To evaluate RESV's ability to modulate GBM-associated signaling pathways and biological processes.
Main Methods:
- Literature review on Resveratrol's antitumor activities.
- Analysis of Resveratrol's impact on PI3K/Akt, MAPK, Nanog, STAT3, and Wnt pathways.
- Assessment of Resveratrol's effects on apoptosis, autophagy, angiogenesis, and stemness in GBM cells.
Main Results:
- Resveratrol exhibits significant antitumor activity against GBM.
- RESV demonstrates potential in regulating multiple signaling pathways implicated in GBM progression.
- RESV can induce apoptotic cell death and inhibit GBM cell proliferation.
Conclusions:
- Resveratrol holds promise for glioblastoma treatment, potentially overcoming therapeutic resistance.
- RESV can re-sensitize GBM cells to radiotherapy and enhance chemotherapy efficacy.
- Targeting signaling pathways with RESV offers a novel strategy to inhibit GBM progression and improve patient survival.
